Dr. Jennifer Bath, an expert in antibody discovery, as well as translational work in infectious disease, explains why leaving a tenured professorship was a price worth paying to become the CEO of ImmunoPrecise Antibodies (IPA).
After President Trump touted it as a quote “cure” for coronavirus, Regeneron is seeking emergency use authorization for its antibody treatment. For more on the latest coronavirus antibody treatments, we spoke to Doctor Jennifer Bath, expert in antibody based therapeutics and the CEO of ImmunoPrecise.
Jennifer Bath, CEO of ImmunoPrecise joins BNN Bloomberg to discuss antibody treatments – something we’re hearing a lot about lately. She also talks about the COVID-19 antibody treatment her business is working on.
ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study.
To meet the global demand for COVID-19 spike protein needed for antibody test kits, University of Victoria plant biologist Peter Constabel has turned to an unexpected source: a relative of the tobacco plant.
PolyTope mAb Therapy™, a defined antibody combination designed to target multiple epitopes and mechanisms of viral evasion, and enabled by IPA’s discovery platforms (including B Cell Select™ and DeepDisplay™) and ImmunoPrecise subsid…